Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem
cell transplant - a procedure where the patient is treated with high dose chemotherapy and
then their own (autologous) stem cells are transplanted back into their body. Patients with
multiple myeloma and high risk genes, always relapse after an autologous transplant and often
die within two years from the time of their transplant. A different type of transplant
allogeneic) using donor cells, may work better for high-risk Multiple Myeloma, because the
donor cells may help kill the lymphoid cancer cells.
This study will investigate if a matched donor stem cell transplant using a newer, reduced
toxicity, chemotherapy (Flu-Bu4) is a feasible option for patients with high risk, Multiple
Myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.